Cathie Wood's $362 Million CRISPR Bet: Hidden Catalyst
Cathie Wood’s big bet on CRISPR Therapeutics signals more than faith in gene editing. This article digs into the unde...
We compare Dividend Growth ETFs to reveal the one with the lowest expense ratio, helping you maximize net returns without sacrificing growth.
28,176 articlesCathie Wood’s big bet on CRISPR Therapeutics signals more than faith in gene editing. This article digs into the unde...
The Trek CEO’s daily routine fuses a lifelong love of reading with a belief that business should serve society, not j...
SpaceX gears up for a public listing with a potential $75 billion raise and a multi-trillion-dollar valuation. Nasdaq...
Two neighboring Texas towns face a high-stakes fight over a proposed $10 billion AI data center, pitting rural govern...
Take-Two CEO Strauss Zelnick is directing a record-setting $1.5 billion launch budget for GTA VI, a move investors wi...
A major stake in Nvidia from a notable Tesla bull underscores confidence in the AI chip leader’s growth trajectory, e...
A Melius analyst warns that Microsoft's Copilot leadership reshuffle may signal deeper misalignment between AI ambiti...
Bridgewater Associates tightened its tech exposure in the latest 13F filing, cutting stakes in Microsoft, Meta, and A...
Nvidia is reportedly developing a chip platform focused on AI inference workloads amid a shift in the AI landscape. E...
When a big fund buys in after a sharp drop, it sends a message about confidence and risk. This piece breaks down what...
As higher interest rates bite into fixed retiree incomes, Suze Orman argues that paying only the minimum on credit ca...
AbbVie’s Apogee deal has revived takeover chatter. Three Nasdaq-listed biotech players are emerging as plausible biot...